Stock Track | Tandem Diabetes Care Soars 6.70% on Strong Q4 Earnings Beat and Upbeat 2026 Guidance

Stock Track

Feb 20

Tandem Diabetes Care's stock surged 6.70% in post-market trading, driven by the company's fourth-quarter and full-year 2025 financial results that significantly exceeded analyst expectations.

The diabetes technology firm reported an adjusted loss per share of $(0.01) for Q4 2025, beating the consensus estimate of $(0.08) by 87.8%. Quarterly sales reached $290.4 million, surpassing estimates of $277.03 million. Key profitability metrics showed marked improvement, with Q4 adjusted operating income coming in at $8.3 million against an estimated loss, and gross margin hitting a record 58%.

Investor sentiment was further bolstered by the company's financial guidance for the full year 2026. Tandem Diabetes Care projects sales between approximately $1.065 billion and $1.085 billion and anticipates an adjusted EBITDA margin of 5% to 6%. The positive outlook is supported by recent operational updates, including the global rollout of its t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus sensor and strong international sales growth of 17% in the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1183690359"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183690359\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1183690359?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-20 11:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183690359","market":"us","top_or_hot":-1,"title":"Stock Track | Tandem Diabetes Care Soars 6.70% on Strong Q4 Earnings Beat and Upbeat 2026 Guidance","media":"Stock Track","content":"<p>Tandem Diabetes Care's stock surged 6.70% in post-market trading, driven by the company's fourth-quarter and full-year 2025 financial results that significantly exceeded analyst expectations.</p><p>The diabetes technology firm reported an adjusted loss per share of $(0.01) for Q4 2025, beating the consensus estimate of $(0.08) by 87.8%. Quarterly sales reached $290.4 million, surpassing estimates of $277.03 million. Key profitability metrics showed marked improvement, with Q4 adjusted operating income coming in at $8.3 million against an estimated loss, and gross margin hitting a record 58%.</p><p>Investor sentiment was further bolstered by the company's financial guidance for the full year 2026. Tandem Diabetes Care projects sales between approximately $1.065 billion and $1.085 billion and anticipates an adjusted EBITDA margin of 5% to 6%. The positive outlook is supported by recent operational updates, including the global rollout of its t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus sensor and strong international sales growth of 17% in the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tandem Diabetes Care Soars 6.70% on Strong Q4 Earnings Beat and Upbeat 2026 Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tandem Diabetes Care Soars 6.70% on Strong Q4 Earnings Beat and Upbeat 2026 Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-20 11:27</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tandem Diabetes Care's stock surged 6.70% in post-market trading, driven by the company's fourth-quarter and full-year 2025 financial results that significantly exceeded analyst expectations.</p><p>The diabetes technology firm reported an adjusted loss per share of $(0.01) for Q4 2025, beating the consensus estimate of $(0.08) by 87.8%. Quarterly sales reached $290.4 million, surpassing estimates of $277.03 million. Key profitability metrics showed marked improvement, with Q4 adjusted operating income coming in at $8.3 million against an estimated loss, and gross margin hitting a record 58%.</p><p>Investor sentiment was further bolstered by the company's financial guidance for the full year 2026. Tandem Diabetes Care projects sales between approximately $1.065 billion and $1.085 billion and anticipates an adjusted EBITDA margin of 5% to 6%. The positive outlook is supported by recent operational updates, including the global rollout of its t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus sensor and strong international sales growth of 17% in the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TNDM","symbol_name":"Tandem Diabetes","start_time":0,"source_url":"","article_id":"1183690359","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183690359","pubTimestamp":1771558068,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tandem Diabetes Care's stock surged 6.70% in post-market trading, driven by the company's fourth-quarter and full-year 2025 financial results that significantly exceeded analyst expectations.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TNDM":"Tandem Diabetes"},"translate_title":"股票追踪|Tandem Diabetes Care因强劲的第四季度盈利和乐观的2026年指引而飙升6.70%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TNDM":1},"content_text":"Tandem Diabetes Care's stock surged 6.70% in post-market trading, driven by the company's fourth-quarter and full-year 2025 financial results that significantly exceeded analyst expectations.The diabetes technology firm reported an adjusted loss per share of $(0.01) for Q4 2025, beating the consensus estimate of $(0.08) by 87.8%. Quarterly sales reached $290.4 million, surpassing estimates of $277.03 million. Key profitability metrics showed marked improvement, with Q4 adjusted operating income coming in at $8.3 million against an estimated loss, and gross margin hitting a record 58%.Investor sentiment was further bolstered by the company's financial guidance for the full year 2026. Tandem Diabetes Care projects sales between approximately $1.065 billion and $1.085 billion and anticipates an adjusted EBITDA margin of 5% to 6%. The positive outlook is supported by recent operational updates, including the global rollout of its t:slim X2 pump integration with Abbott's FreeStyle Libre 3 Plus sensor and strong international sales growth of 17% in the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}